72 results about "Axitinib" patented technology

The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib. In some embodiments, the agent binds to a receptor involved in signalling by at least one of IL-3, G-CSF and GM-CSF. In some embodiments, the agent is a mutein selected from the group consisting of IL-3 muteins, G-CSF muteins and GM-CSF muteins. In some embodiments, the mutein is an IL-3 mutein. In some embodiments, the agent is a soluble receptor which is capable of binding to IL-3.

The invention provides a method for preparing axitinib tablets through a dry powder tabletting method.The method comprises the steps that 1, raw and auxiliary material components comprising 0.5 wt%-3 wt% of axitinib, 85 wt%-97 wt%of a diluent, 1 wt%-10 wt% of a disintegrating agent and 0.25 wt%-2 wt% of a lubricating agent are weighed; 2, the axitinib and the auxiliary materials are mixed in batches; 3, a mixture obtained in the step 2 is tabletted and coated to obtain the axitinib tablets, wherein the particle size D90 of the axitinib is smaller than or equal to 60 micrometers, the particle size of at least 90% of the diluent is smaller than 240 micrometers, the particle size of at least 30% of the diluent ranges from 50 micrometers to 140 micrometers, and the particle size of 2-20 wt% of the diluent is smaller than 32 micrometers.The method for preparing the axitinib tablets through the dry powder tabletting method is simple and reliable; the axitinib tablets prepared through the method are uniform in content, small in tablet weight difference, low in tablet cracking rate and qualified in dissolution curve, and the related substance content meets the specification; meanwhile, the method has the advantages that the technology is simple, the production period is short, the production efficiency is improved, and the cost is reduced.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)), lung cancer (e.g., non-small cell lung cancer (NSCLC)), bladder cancer (e.g., urothelial bladder cancer (UBC)), liver cancer (e.g., hepatocellular carcinoma (HCC)), ovarian cancer, or breast cancer (e.g., triple-negative breast cancer (TNBC))). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g., atezolizumab (MPDL3280A)) or a PD-1 binding antagonist (e.g., anti-PD-1 antibody)), or with an angiogenesis inhibitor (e.g., a VEGF antagonist (e.g., a VEGFR inhibitor, (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib)))).

The invention provides a pharmaceutical composition containing sunitinib as well as a preparation and an application of the pharmaceutical composition. On the basis of the original sunitinib, at leastone tyrosine kinase receptor inhibitor, especially apatinib and / or axitinib, is further added to generate a very significant synergistic effect with the sunitinib, so that the proliferation of cancercells is obviously inhibited, and the sunitinib has very significant killing efficiency on the cancer cells. The pharmaceutical composition provided by the invention can obviously improve the problemof serious drug resistance caused by singly adopting sunitinib in the prior art and the problem of obviously reduced treatment effect when the conventional use amount of sunitinib is reduced; clinical treatment efficiency is greatly improved, treatment toxic and side effects of a patient are reduced, a new scheme is provided for clinical treatment, and the traditional Chinese medicine compositionhas very wide market prospects and extremely important social significance.

The invention relates to a pharmaceutical composition containing crenolanib and application of the pharmaceutical composition. The present invention relates to the use of a combination comprising crenolanib or a salt thereof and a VEGF / VEGFR inhibitor of non-axitinib for the preparation of a medicament for the treatment of proliferative diseases, wherein the crenolanib and the VEGF / VEGFR inhibitorof non-axitinib are provided for a subject in at least one of a sequential or simultaneous manner for treating proliferative diseases, and the subject is a human subject.

The invention provides an axitinib-contained nanofiber electrospun membrane. The nanofiber electrospun membrane consists of axitinib, collagen and polycaprolactone. The invention further provides a preparation method and application of the nanofiber electrospun membrane. The nanofiber electrospun membrane has good biocompatibility, can be degraded and absorbed and can remarkably inhibit blood vessel generation, and therefore the problem that cartilages are prone to ossification when regenerated in a subcutaneous environment is solved.

The invention relates to use of axitinib and an analogue thereof in preparation of a blood-brain barrier permeability regulating agent. The blood-brain barrier permeability regulating agent can reducethe blood-brain barrier permeability and promote the recovery of a blood-brain barrier function from a pathological damage state to an approximate physiological barrier state. The axitinib and the analogue thereof, by suppressing vascular endothelial cell growth factor-phosphatidylinositol kinase-protein kinase B signaling pathway, can reduce the down-regulating degree of pathological blood brainbarrier tightly attached protein Claudin-5 / Occludin and reduce the blood-brain barrier permeability. The blood-brain barrier permeability regulating agent can be used for treatment of related diseases that cause changes in the blood-brain barrier permeability.

The invention discloses an application of a nanofiber membrane loaded with a small molecule drug for inhibiting a vascular endothelial growth factor and / or inhibiting a vascular endothelial growth factor receptor to preparation of a surgical postoperative anti-adhesion medical instrument. The nanofiber membrane has the advantages that the nanofiber membrane provided in the invention is good in biocompatibility, excellent in mechanical property, flexible and smooth after encountering water, good in air permeability and capable of effectively preventing the heart from adhering to surrounding tissues. In addition, the nanofiber membrane can also be applied to adhesion prevention in other surgical operations for abdominal cavities, pelvic cavities, tendons and the like.